Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to filter the trials based on location, phase of development, or drug name, category or target
Mirvetuximab Soravtansine
No preference
No preference

Results

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT04209855IIIPlatinum resistant or refractory FRalpha+ high grade serous ovarian cancer, excluding primary platinum refractoryMIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha ExpressionAZ, CO, FL, IL, KY, LA, MD, MA, MI, MN, NJ, NC, OH, OK, OR, PA, RI, TX, VA, WA, WVView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Mirvetuximab SoravtansineAnti-FOLR1-mab Maytansinoid Conjugate, IMGN853, M9346A-sulfo-SPDB-DM4ADC: anti-FOLR1 + microtubule destabilizer (DM4)Clinical Trials
NCT04296890IIIPlatinum resistant or refractory FRalpha+ ovarian cancer with prior bevacizumab, excluding primary platinum refractorySORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha ExpressionAZ, IL, MD, MA, NJ, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Mirvetuximab SoravtansineAnti-FOLR1-mab Maytansinoid Conjugate, IMGN853, M9346A-sulfo-SPDB-DM4ADC: anti-FOLR1 + microtubule destabilizer (DM4)Clinical Trials
NCT02996825IPlatinum resistant or refractory FRalpha+ advanced ovarian cancer, excluding primary platinum refractoryA Phase I Dose-Escalation Safety and Tolerability Study of MirvetuximabSoravtansine (IMGN853) and Gemcitabine in Patients With FRa-positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial Cancer, or Triple Negative Breast Cancer (TNBC)CAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Mirvetuximab SoravtansineAnti-FOLR1-mab Maytansinoid Conjugate, IMGN853, M9346A-sulfo-SPDB-DM4ADC: anti-FOLR1 + microtubule destabilizer (DM4)Clinical Trials
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
NCT03552471IPlatinum resistant or refractory FRalpha+ ovarian cancer, excluding primary platinum refractory (in expansion)Phase I Study of Mirvetuximab Soravtansine (IMGN853) and Rucaparib for Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal CancerOHView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Mirvetuximab SoravtansineAnti-FOLR1-mab Maytansinoid Conjugate, IMGN853, M9346A-sulfo-SPDB-DM4ADC: anti-FOLR1 + microtubule destabilizer (DM4)Clinical Trials
RucaparibAG-014699, PF 01367338, CO-338, RubracaPARP inhibitorApproved in Ovarian Cancer

If you have any questions or would like help with your search, please call us at: 858-264-5124 or email us at patientsupport@clearityfoundation.org.